Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts

Authors

  • Thomas F. Kresina,

    Corresponding author
    1. Center on AIDS and other Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Department of Health and Human Services, Bethesda, MD
    • Center on AIDS and other Medical Consequences of Drug Abuse (CAMCODA), 6001 Executive Blvd., National Institute on Drug Abuse, Bethesda, MD 20892
    Search for more papers by this author
    • fax: (301) 443-2599

  • Leonard B. Seeff,

    1. National Institute on Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
    Search for more papers by this author
  • Henry Francis

    1. Center on AIDS and other Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Department of Health and Human Services, Bethesda, MD
    Search for more papers by this author

Abstract

Treatment regimens for both substance abuse and hepatitis C infection are complex and evolving. New pharmacotherapy for opioid addiction allows for office-based treatment and, thus, an opportunity for expanded treatment in the context of hepatitis C infection. The current article addresses the newly evolving, complex issues in the medical management of hepatitis C and injection drug use. (HEPATOLOGY 2004;40:516–519.)

Ancillary